The global Checkpoint Inhibitor Refractory Cancer Market size is predicted to reach US$ 38.69 billion in 2023 and is projected to expand at a CAGR of 11.26% between 2023 and 2033, ultimately reaching around US$ 112.43 billion by 2033. This growth is driven by the increasing demand for expanded indications of existing immunotherapies, including checkpoint inhibitors such as PD-1/PD-L1, which provide a focused approach to reducing toxicity and improving efficacy.
For In-depth insights, Download Sample Copy@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16133
The effectiveness of checkpoint inhibitors, along with the high prevalence of cancer, is a significant factor responsible for the rise in market revenue. Technological advancements and innovations are expected to further accelerate market growth. Additionally, an increase in R&D activities, commercial success of upcoming therapies, a surge in the usage of approved checkpoint inhibitor therapies in the 7MM, and a rise in the cases of various cancers where checkpoint inhibitors are used are projected to fuel the revenue share of the market.
Several companies are actively developing new drug therapy options for treating different types of Checkpoint Inhibitor Refractory Cancers, including BerGenBio, OncoSec Medical, Mirati Therapeutics, CatalYm, and Checkmate Pharmaceuticals. Pembrolizumab (KEYTRUDA) is experiencing a surge in demand globally due to its proven efficacy in treating FDA-Approved indications such as head and neck squamous cell cancer (HNSCC), non-small cell lung cancer (NSCLC), and melanoma. Consequently, market players are investing heavily in developing these products, and this trend is expected to continue.
The growing burden of cancer on a global level is increasing the use of checkpoint inhibitors as front-line treatments for several types of cancer. Hence, with the increase in the incidence of cancer, the use of checkpoint inhibitors is also expected to rise, fostering market growth in the coming years.
Ask More About This Market’s Geographical Distribution Along With a Detailed Analysis of the Top Regions@ https://www.futuremarketinsights.com/ask-question/rep-gb-16133
Key Takeaways from the Market Study
- Global Checkpoint Inhibitor Refractory Cancer Market was valued at US$ 781.0 Billion by 2022-end
- From 2018 to 2022, the market demand expanded at a CAGR of 5.5%
- By Application, the Non-Small Cell Lung segment of the market constitutes the bulk of the market with a market share of 37%
- By End-User, the Hospital Pharmacies segment dominates the market with a share of 48.3%
- From 2023 to 2033, Checkpoint Inhibitor Refractory Cancer sales are expected to flourish at a CAGR of 11.26%.
- By 2033, the market value of Checkpoint Inhibitor Refractory Cancer is expected to reach US$ 112.43 Billion.
A rapid increase in the global prevalence of several cancers globally is one of the major factors that is expected to escalate the growth of the checkpoint inhibitor refractory cancer market in the forthcoming years, remarks an FMI analyst.
Competitive Landscape
Prominent players in the Checkpoint Inhibitor Refractory Cancer market are Bristol-Myers Squibb, AstraZeneca, Merck, Genentech/Hoffmann-La Roche, Regeneron Pharmaceuticals, Merck KGaA, Pfizer, Bristol-Myers Squibb, Janssen Research and Development, LLC., 4D pharma plc., 4SC AG, OncoSec Medical, Mirati Therapeutics, Ascentage Pharma Group, and ENB Therapeutics, Inc., among others.
Recent Developments:
- In January 2020, Merck & Co. acquired ArQule Inc., a company that develops therapeutics based on its proprietary Activated Checkpoint Therapy platform.
- In July 2019, Sanofi signed an agreement with Roche for the exclusive over-the-counter (OTC) rights to Tamiflu for the prevention and treatment of influenza or flu in the United States.
Contact Sales for Further Assistance in Purchasing this Report@ https://www.futuremarketinsights.com/checkout/16133
Key Segments Covered in the Checkpoint Inhibitor Refractory Cancer Industry Analysis
Checkpoint Inhibitor Refractory Cancer Market by Type:
- PD-1 Inhibitors
- PD-L1 Inhibitors
Checkpoint Inhibitor Refractory Cancer Market by Application:
- Hodgkin Lymphoma
- Kidney Cancer
- Melanoma
- Non-Small Cell Lung Cancer
- Others
Checkpoint Inhibitor Refractory Cancer Market by End-User:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
About Future Market Insights, Inc.
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
